REGENERON PHARMACEUTICALS, INC. Cash & Equivalents 2007-2025 | REGN
What is cash & equivalents?
Cash and cash equivalents can be defined as the most liquid assets on a company's balance sheet, including cash on hand and short-term investments maturing within 90 days.
What is REGENERON PHARMACEUTICALS, INC.'s current cash & equivalents?
REGENERON PHARMACEUTICALS, INC. (REGN) annual cash & equivalents for 2025 was $3.12B, a 25.32% increase from 2024. REGENERON PHARMACEUTICALS, INC. cash & equivalents for the quarter ending December 31, 2025 was $3.12B.
What was REGENERON PHARMACEUTICALS, INC.'s cash & equivalents in 2024?
REGENERON PHARMACEUTICALS, INC. annual cash & equivalents for 2024 was $2.49B, a 8.86% decline from 2023.
What was REGENERON PHARMACEUTICALS, INC.'s cash & equivalents in 2023?
REGENERON PHARMACEUTICALS, INC. annual cash & equivalents for 2023 was $2.73B, a 12.10% decline from 2022.
What is REGENERON PHARMACEUTICALS, INC.'s 5-year cash & equivalents CAGR?
REGENERON PHARMACEUTICALS, INC. cash & equivalents grew at a compound annual growth rate (CAGR) of 7.29% from FY2020 to FY2025, going from $2.19B to $3.12B over 5 years.
Year-over-year comparison from 10-K annual reports
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $3.12B | +25.3% | 10-K |
| FY2024 | $2.49B | -8.9% | 10-K |
| FY2023 | $2.73B | -12.1% | 10-K |
| FY2022 | $3.11B | +7.6% | 10-K |
| FY2021 | $2.89B | +31.5% | 10-K |
| FY2020 | $2.19B | +35.6% | 10-K |
| FY2019 | $1.62B | +10.2% | 10-K |
| FY2018 | $1.47B | +80.6% | 10-K |
| FY2017 | $812.7M | +51.8% | 10-K |
| FY2016 | $535.2M | -33.9% | 10-K |
| FY2015 | $809.1M | +24.7% | 10-K |
| FY2014 | $648.7M | +21.1% | 10-K |
| FY2013 | $535.6M | +132.6% | 10-K |
| FY2012 | $230.3M | -52.4% | 10-K |
| FY2011 | $483.6M | +329.6% | 10-K |
| FY2010 | $112.6M | -45.6% | 10-K |
| FY2009 | $207.1M | -16.4% | 10-K |
| FY2008 | $247.8M | -50.3% | 10-K |
| FY2007 | $498.9M | - | 10-K |